-
Repros Therapeutics Posts Q1 Loss Per Share Of $0.41 Vs. Loss $0.17 Prior Year
5/10/2013
|
-
Repros Therapeutics Reports Second Pivotal Androxal Study Fully Enrolled Ahead Of Schedule
5/2/2013
|
|
|
|
|
|
|
|
|
|
|
-
Repros Therapeutics Says AUA Accepts Key Data On Androxal For Podium Presentation At San Diego Annual Meeting
3/25/2013
|
-
Repros Therapeutics Posts Q4 Loss/Share Of $0.47 Vs. Loss $0.22 Last Year
3/18/2013
|
|
|